Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 5:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 120 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Selective Serotonin Uptake Inhibitors ("SSRI") Clear all
Completed Phase 4 Interventional Results available

Treating Suicidal Behavior and Self-Mutilation in People With Borderline Personality Disorder

NCT00533117
View directory record Official record
Conditions
Borderline Personality Disorder
Interventions
Fluoxetine, Dialectical Behavior Therapy, Supportive psychotherapy
Drug · Behavioral
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 55 Years
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 5, 2024 · Synced Oct 4, 2026, 5:46 PM EDT
Completed Phase 4 Interventional Results available

Trial to Compare Time to Response in the Symptoms of Anxiety to Concomitant Treatment With Niravam™ and an SSRI or SNRI to Treatment With an SSRI or SNRI Alone in Subjects With Generalized Anxiety Disorder or Panic Disorder

NCT00266409
View directory record Official record
Conditions
Generalized Anxiety Disorder, Panic Disorder
Interventions
Niravam, SSRI/SNRI
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 27, 2014 · Synced Oct 4, 2026, 5:46 PM EDT
Completed Phase 1 Interventional

A Pharmacodynamic Study of Dapoxetine Concomitantly Administered in Participants Taking Terazosin

NCT01366664
View directory record Official record
Conditions
Ejaculation
Interventions
Treatment sequence 2, Treatment sequence 1
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
6
States / cities
Anniston, Alabama • Tempe, Arizona • Costa Mesa, California + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2014 · Synced Oct 4, 2026, 5:46 PM EDT
Completed Not applicable Interventional Results available

Methylphenidate for Depressed Cancer Patients Receiving Palliative Care

NCT00129467
View directory record Official record
Conditions
Depression, Palliative Care, Cancer, Mental Disorder
Interventions
Methylphenidate, Placebo, Selective Serotonin Uptake Inhibitor (SSRI)
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 24, 2015 · Synced Oct 4, 2026, 5:46 PM EDT
Completed Phase 4 Interventional Results available

Escitalopram in the Treatment of Dysthymic Disorder, Double Blind

NCT00220701
View directory record Official record
Conditions
Dysthymic Disorder
Interventions
Lexapro (escitalopram)
Drug
Lead sponsor
St. Luke's-Roosevelt Hospital Center
Other
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 11, 2015 · Synced Oct 4, 2026, 5:46 PM EDT
Completed Not applicable Interventional Results available

Adding Exercise to Antidepressant Medication Treatment for Depression

NCT00076258
View directory record Official record
Conditions
Depression
Interventions
SSRI + LD, SSRI + PHD
Behavioral
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 23, 2020 · Synced Oct 4, 2026, 5:46 PM EDT
Completed Phase 1 Interventional Results available

A Study to Test How Well Different Doses of BI 1569912 Are Tolerated and How Well They Work in People With Depression Who Take Anti-depressive Medication

NCT04937829
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
5 mg BI 1569912, 20 mg BI 1569912, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 65 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
10
States / cities
Garden Grove, California • Torrance, California • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 4, 2026, 5:46 PM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate the Effect of AFQ056 in Obsessive Compulsive Disorder (OCD) Patients Resistant to Selective Serotonin Reuptake Inhibitor (SSRI) Therapy

NCT01813019
View directory record Official record
Conditions
Patient Diagnosed With OCD and Resistant to SSRI Treatment, Failed SSRI Over 12 Weeks at Appropriate Doses
Interventions
AFQ056, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
3
States / cities
San Diego, California • Watertown, Massachusetts • Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Jan 2, 2017 · Synced Oct 4, 2026, 5:46 PM EDT
Completed Phase 3 Interventional Results available

A Study in Participants With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor

NCT01185340
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
LY2216684, Placebo, SSRI
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,056 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
20
States / cities
Garden Grove, California • Oakland, California • Temecula, California + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2018 · Synced Oct 4, 2026, 5:46 PM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder (MDD)

NCT01157078
View directory record Official record
Conditions
Major Depressive Disorder, Depression
Interventions
TC-5214, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
319 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
37
States / cities
Tuscaloosa, Alabama • Tucson, Arizona • Little Rock, Arkansas + 34 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2014 · Synced Oct 4, 2026, 5:46 PM EDT
Completed Phase 4 Interventional Results available

Study of 6(S)-5-MTHF Among Selective Serotonin Reuptake Inhibitor-Resistant Outpatients With Major Depressive Disorder

NCT00955955
View directory record Official record
Conditions
Depression
Interventions
6(S)-5-MTHF(Deplin), Placebo
Other
Lead sponsor
George I. Papakostas
Other
Eligibility
18 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
6
States / cities
San Diego, California • Chicago, Illinois • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2017 · Synced Oct 4, 2026, 5:46 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Depression-Diabetes Mechanisms: Urban African Americans

NCT00209170
View directory record Official record
Conditions
Diabetes, Depression
Interventions
Beating the Blues, Escitalopram, Placebo
Behavioral · Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 81 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 29, 2015 · Synced Oct 4, 2026, 5:46 PM EDT
Completed Phase 2 Interventional Results available

Citalopram to Enhance Cognition in HD

NCT00271596
View directory record Official record
Conditions
Huntington Disease, Chorea, Executive Dysfunction
Interventions
20mg daily citalopram, Placebo
Drug
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 75 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
3
States / cities
Scottsdale, Arizona • Iowa City, Iowa • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Mar 13, 2013 · Synced Oct 4, 2026, 5:46 PM EDT
Completed Phase 4 Interventional Results available

Combining Medications to Enhance Depression Outcomes

NCT00590863
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
SSRI + placebo, Escitalopram + Bupropion SR, Venlafaxine XR + Mirtazapine
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 75 Years
Enrollment
665 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
15
States / cities
Tuscaloosa, Alabama • Harbor City, California • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2014 · Synced Oct 4, 2026, 5:46 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Allopregnanolone and Dynamic GABA-A Receptor Plasticity in Selective Serotonin Reuptake Inhibitor Responsive Premenstrual Dysphoric Disorder

NCT06704594
View directory record Official record
Conditions
Premenstrual Dysphoric Disorder (PMDD)
Interventions
sertraline 50 mg daily, Placebo Oral Tablet
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
288 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
2
States / cities
Baltimore, Maryland • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 4, 2026, 5:46 PM EDT
Terminated Phase 1 Interventional

A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adolescents With Major Depressive Disorder Who Have an Inadequate Response to Selective Serotonin Reuptake Inhibitor (SSRI) and Psychotherapy

NCT04951609
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Seltorexant, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
12 Years to 17 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
12
States / cities
Phoenix, Arizona • Anaheim, California • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Oct 4, 2026, 5:46 PM EDT
Completed Phase 2 Interventional Results available

A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy

NCT03321526
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
JNJ-42847922, Placebo Matching to JNJ-42847922, Quetiapine XR, Placebo Matching to Quetiapine XR, Selective Serotonin Reuptake Inhibitor (SSRI), Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
50
States / cities
Phoenix, Arizona • Tempe, Arizona • Rogers, Arkansas + 41 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 4, 2026, 5:46 PM EDT
Completed Phase 4 Interventional

Evaluation of Clonazepam and Paroxetine for Panic Disorder With Depression

NCT00031317
View directory record Official record
Conditions
Panic Disorder
Interventions
Paroxetine, Clozapine
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 4, 2026, 5:46 PM EDT
Completed No phase listed Observational

A Study Following Women in Menopause Treated With a Non-hormonal Therapy for Hot Flashes and Night Sweats

NCT06049797
View directory record Official record
Conditions
Hot Flashes
Interventions
Fezolinetant, Paroxetine, Citalopram, Escitalopram, Desvenlafaxine, Venlafaxine, Gabapentin, Clonidine, Pregabalin, Oxybutynin, Any other SSRI/SNRI not already specified, Any other non-hormonal pharmacologic therapy prescribed for the treatment of VMS not included in a category above
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
40 Years to 75 Years · Female only
Enrollment
999 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
48
States / cities
Birmingham, Alabama • Phoenix, Arizona • Lomita, California + 39 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 4, 2026, 5:46 PM EDT
Completed Not applicable Interventional

Preventing Post-Stroke Depression

NCT00071643
View directory record Official record
Conditions
Depression, Cerebrovascular Accident
Interventions
Problem Solving Therapy, Escitalopram, Placebo
Behavioral · Drug · Other
Lead sponsor
Robert G. Robinson
Other
Eligibility
31 Years to 89 Years
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
3
States / cities
Chicago, Illinois • Iowa City, Iowa • White Plains, New York
Source: ClinicalTrials.gov public record
Updated Sep 5, 2017 · Synced Oct 4, 2026, 5:46 PM EDT
Completed Phase 1Phase 2 Interventional Results available

An Adaptive Treatment Strategy for Adolescent Depression-Continuation

NCT02017535
View directory record Official record
Conditions
Adolescent Depression
Interventions
Fluoxetine, Interpersonal Psychotherapy
Drug · Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
12 Years to 18 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 23, 2020 · Synced Oct 4, 2026, 5:46 PM EDT
Terminated Phase 2 Interventional Results available

Selective Serotonin Reuptake Inhibitors (SSRIs) in Borderline Personality Disorder

NCT01103180
View directory record Official record
Conditions
Borderline Personality Disorder
Interventions
Escitalopram
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 40 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 14, 2019 · Synced Oct 4, 2026, 5:46 PM EDT
Completed Phase 2 Interventional Results available

Combined Treatment for Alcohol-Dependent Individuals With PTSD

NCT00262223
View directory record Official record
Conditions
Stress Disorders, Post-Traumatic, Alcohol Abuse, Substance-Related Disorders
Interventions
Seeking Safety, Sertraline, Pill placebo
Behavioral · Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 3, 2020 · Synced Oct 4, 2026, 5:46 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Differentiating Unipolar and Bipolar Depression in Young Adults Using fMRI

NCT01811147
View directory record Official record
Conditions
Bipolar Disorder, Major Depression
Interventions
Selective Serotonin Reuptake Inhibitor (SSRI)
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
15 Years to 30 Years
Enrollment
192 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2018
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 2, 2019 · Synced Oct 4, 2026, 5:46 PM EDT